RABAC1

Across TCGA pan-cancer cohorts, RABAC1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RABAC1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RABAC1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RABAC1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LSCC are the cancer types where RABAC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.618	0.204	.001	25	view →
COAD	DFS	Median	III,IV	1.000	0.893	.038	18	view →
LSCC	DFS	Median	II,III,IV	0.843	0.999	.010	6	view →
CCRCC	DFS	Quartile	III,IV	0.241	0.584	.010	4	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →
LUAD	DFS	Median	All	0.548	0.724	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RABAC1–PDAC (OS)

Open the PDAC breakdown →